| 1 |
Advancing the Use of Mobile Technologies in Clinical Trials: Recommendations from the Clinical Trials Transformation Initiative
Philip Coran et al. · Digital Biomarkers
Open access |
6 Nov 2019 |
71 |
| 2 |
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
Michael Charles Heinrich, Janice Patterson, Carol Beadling et al. · Clinical Sarcoma Research
Open access |
5 Mar 2019 |
49 |
| 3 |
Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry
Jerry W. Call, Christopher D Walentas, Jens C. Eickhoff et al. · BMC Cancer
Open access |
19 Mar 2012 |
49 |
| 4 |
Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry
Jerry W. Call, Yu Wang, Denisse Montoya et al. · Clinical Sarcoma Research
Open access |
2 Apr 2019 |
33 |
| 5 |
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors
César Serrano, Sara Rothschild, Guillermo Javierre Villacampa et al. · Nature Medicine
|
12 Oct 2023 |
29 |
| 6 |
Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)
Brett Hauber, Juan Marcos González, John H. Coombs et al. · Patient Preference and Adherence
Open access |
Jun 2011 |
17 |
| 7 |
Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry
Emelia R. Stuart, Sudeep Banerjee, Jorge de la Torre et al. · Journal of Surgical Oncology
Open access |
11 Jul 2019 |
12 |
| 8 |
Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study
Jerry W. Call, Norman J. Scherzer, P. David Josephy et al. · Journal of Gastrointestinal Cancer
Open access |
27 Nov 2009 |
12 |
| 9 |
Mutational Testing in Gastrointestinal Stromal Tumor
Yu Wang, Jerry W. Call · Current Cancer Drug Targets
|
27 Mar 2019 |
11 |
| 10 |
Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry
Sydney Stern, Patrick McKenzie, Nicholas Matthew Bernthal et al. · Future Oncology
Open access |
8 Apr 2025 |
9 |
| 11 |
A Review of Genomic Testing and SDH ‐ Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
Vaia Florou, Michelle F. Jacobs, Ruth Therese Casey et al. · Cancer Medicine
Open access |
Feb 2025 |
9 |
| 12 |
Anticipating the COVID-19-related surge in cancer care demand is urgent in Latin America and the Caribbean
Cristian A. Herrera, Piga Fernández, Afsan Bhadelia et al. · The Lancet Oncology
Open access |
3 Sep 2021 |
7 |
| 13 |
Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma
Denisse Evans, Sara Rothschild, Carol Tordella et al. · American Society of Clinical Oncology Educational Book
Open access |
Jun 2024 |
4 |
| 14 |
Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations
Andrea Napolitano et al. · JAMA Oncology
Open access |
26 Feb 2026 |
3 |
| 15 |
Novel trial designs for patients with gastrointestinal stromal tumor
César Serrano, Stanley Rothschild, Guillermo Javierre Villacampa et al. · ESMO Open
Open access |
2024 |
3 |
| 16 |
Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of life raft group members
Denisse Montoya, Jerry W. Call, Jennily Eshak et al. · BMC Gastroenterology
Open access |
15 Nov 2022 |
3 |
| 17 |
1758P Real-world efficacy of imatinib in patients with advanced GIST: The LRG registry
G. Gim, Jerry W. Call, David M Evans et al. · Annals of Oncology
Open access |
Sep 2024 |
2 |
| 18 |
1978P Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
David J. Evans, Jerry W. Call, Satvinder Kaur et al. · Annals of Oncology
Open access |
Oct 2023 |
2 |
| 19 |
Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry
Jerry W. Call, Jonathan W. Wojtkowiak, Denisse Evans et al. · Cancer Investigation
Open access |
4 May 2023 |
2 |
| 20 |
Pediatric patients with tenosynovial giant cell tumor: real-world evidence from an observational registry
Sydney Stern, Patrick McKenzie, Giacomo Giulio Baldi et al. · Orphanet Journal of Rare Diseases
Open access |
30 Jan 2026 |
1 |
| 21 |
Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type
Annalisa Astolfi, Anthony James Gill, Brian P. Rubin et al. · Pathology
Open access |
28 Jun 2022 |
1 |
| 22 |
Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion
Dale Shepard, Sydney Stern, Nicholas M. Bernthal · Advances in Therapy
Open access |
22 Aug 2026 |
0 |
| 23 |
Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
Homma M. Khosroyani et al. · Cancer Research Communications
Open access |
11 Jun 2026 |
0 |
| 24 |
Optimal clinical management of tenosynovial giant cell tumours: a UK perspective
S. Stern, R. Ashford, W. Aston et al. · White Rose Research Online (University of Leeds, The University of Sheffield, University of York)
Open access |
3 Apr 2026 |
0 |
| 25 |
Neighborhood-level disadvantage and disparities in treatment and recurrence in tenosynovial giant cell tumor.
Sydney Stern, Gabriel Tinoco, Sara Rothschild · Journal of Clinical Oncology
|
28 May 2026 |
0 |
| 26 |
Optimal clinical management of tenosynovial giant cell tumours: a UK perspective
Sydney Stern, Robert Ashford, Will Aston et al. · Bone & Joint Open
Open access |
3 Apr 2026 |
0 |
| 27 |
175P Retrospective analysis of 386 patients: An international study by the SDH-deficient GIST consortium
Evelyne Roets, Y. Cheng, TM KHAN et al. · ESMO rare cancers.
Open access |
Mar 2026 |
0 |
| 28 |
Additional file 1 of Pediatric patients with tenosynovial giant cell tumor: real-world evidence from an observational registry
Sydney Stern, Patrick F. McKenzie, Giacomo Giulio Baldi et al. · Figshare
Open access |
2026 |
0 |
| 29 |
IMPACT OF ADVERSE SOCIAL EXPOSOME ON THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR
Sydney Stern, Gabriel Tinoco, Sara Rothschild · ESMO rare cancers.
Open access |
Dec 2025 |
0 |
| 30 |
SURVIVAL OUTCOMES AND MOLECULAR HETEROGENEITY IN EARLY-ONSET GASTROINTESTINAL STROMAL TUMOR (GIST): A LONGITUDINAL COHORT STUDY
Denisse Evans, Christina Ochs, Rachael S. Lowney et al. · ESMO rare cancers.
Open access |
Dec 2025 |
0 |
| 31 |
Systematic elucidation and pharmacologic targeting of non-oncogene dependencies in imatinib-resistant gastrointestinal stromal tumor
Prabhjot Singh Mundi, Adina Grunn, Arsenije Kojadinovic et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
14 Oct 2025 |
0 |
| 32 |
Single Nuclei-Derived Molecular Subtypes of Gastrointestinal Stromal Tumors Correlate with Clinicopathologic Features and Predict Clinical Outcomes
Ashwyn K. Sharma et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
22 Apr 2025 |
0 |
| 33 |
1977P A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Jerry W. Call, D. Gareth Evans, S. Kaur et al. · Annals of Oncology
Open access |
Oct 2023 |
0 |